New York, USA – November 22, 2023 – Globally affecting billions, allergic diseases like allergic rhinitis and asthma underscore the limitations of conventional treatments. In response, Creative Biolabs focuses on propelling the development of allergen immunotherapy. With a profound understanding of allergic reaction mechanisms, Creative Biolabs strives to contribute to the worldwide research initiatives in allergen immunotherapy (AIT).
Allergen immunotherapy represents an innovative treatment modality designed to modulate the immune system’s response to allergens. This approach provides a promising solution for adolescents and adults grappling with moderate to severe rhinitis and moderate asthma.
An expert in non-IgG therapeutic antibody development at Creative Biolabs states, “The induction of immune tolerance, intricately linked to specific IgE and IgA antibody levels, is at the core of allergen immunotherapy. Notably, IgE antibodies play a pivotal role in acute allergic reactions and the development of chronic inflammatory allergic diseases, making the mitigation of IgE-mediated conditions indispensable.”
Proven effective in treating allergic respiratory diseases, anti-IgE antibodies reduce serum IgE and FceRI receptor levels. Creative Biolabs addresses this need with a comprehensive technical platform for non-IgG antibody research, offering global researchers with a spectrum of development services for anti-IgE-based therapy, encompassing purification, production, characterization, and subsequent pharmacokinetic/pharmacodynamic (PK/PD) assessment.
The intricate pathogenesis of allergic diseases, stemming from abnormal immune responses to specific allergens, highlights the vital role of mucosal Immunoglobulin A (IgA). IgA plays a critical role in preventing allergen entry and is involved in various facets of immune regulation and inflammation inhibition.
The dedicated research team at Creative Biolabs is deeply engaged in exploring IgA’s potential role in allergic disease. The team identifies promising novel therapies based on or supplementing IgA enhancement strategies. Leveraging advanced technologies such as phage display and its therapeutic antibody discovery platform, Creative Biolabs extends its non-IgG therapeutic antibody services for allergic disease therapy, including IgA development as a viable therapeutic solution.
“Our nuanced understanding of IgA’s significant role in allergic diseases aims to provide robust support for developing novel treatment methods,” asserted the expert proudly.
Furthermore, Creative Biolabs’ comprehensive non-IgG antibody development platform goes beyond allergen immunotherapy. It offers one-stop services for infectious diseases, cancer, inflammation, and various therapeutic development, facilitating researchers’ experimental processes and resulting in significant time and cost savings.
To learn more about non-IgG antibody development services for allergic diseases, cancer, and infectious diseases, please visit https://non-igg-ab.creative-biolabs.com.
About Creative Biolabs
Creative Biolabs, a globally leading biotechnology company with extensive experience in developing non-IgG therapeutic antibodies for various diseases, is committed to continuous innovation and research.
Media ContactCompany Name: Creative BiolabsContact Person: Candy SwiftEmail: Send EmailPhone: 1-631-830-6441Country: United StatesWebsite: https://non-igg-ab.creative-biolabs.com
